Page 14 - Sun Pharma

US drug regulator inspects Sun Pharmaceutical's Halol plant in Gujarat

Sun Pharma had recalled around 5,000 units of 10 ml vials of testosterone cypionate injections from the US

Nifty Pharma index hits over six-month high; Sun Pharma at 14-month high

Thus far in current week, the Nifty Pharma index outperformed the market by surging 7% against a marginal 0.31% rise in the Nifty 50 index.

Sun Pharma hits 52-week high on USFDA approval, good Q1 results

Sun Pharm hit a 52-week high of Rs 618, up 3%, extending its Tuesday's 7% rally on the BSE.

Earnings upgrades ahead for Sun Pharmaceutical, stock gains nearly 7%

US growth at 8%, despite declining Taro sales, giving confidence that the firm is on a recovery path in America

Sun Pharma posts Rs 9.8 bn Q1 profit, beats estimates as US sales climb

Sales from its US formulations business, which constitutes over a third of total sales, grew 8 per cent from the previous corresponding quarter

Sun Pharma rallies 7% as Q1 profit beats Street estimates

The stock rallied 7% to Rs 600 on the BSE after the company reported a better-than-expected consolidated net profit at Rs 9.83 billion in June quarter.

Pharma shares in focus; Nifty Pharma index hits 6-month high

Divi's Lab, Aurobindo Pharma, Lupin, Dr Reddy's Lab, Sun Pharma, Glenmark Pharma and Cipla from the Nifty pharma index were up in the range of 1% to 3% on the NSE.

Sun Pharma gets USFDA approval to produce cancer injection from Halol site

Halol's non-compliance has held up fresh product approvals from the site for nearly four years, and is partly responsible for the muted growth in the US for Sun.

Markets trade flat, Sun Pharma advances

Markets trade flat, Sun Pharma advances

Sun Pharma nears 52-week high as stock surges 32% in five weeks

The stock was trading 2% higher at Rs 587 on the BSE in otherwise subdued market, trading nears to 52-week high of Rs 609 touched on February 12, 2018.

Sun Pharma sharpens R&D for efficiencies with digital applications

The drug maker has guided for an increase in R&D expenses in FY 19 as it builds a pipeline of specialty products

Pharma shares extend gain in subdued market; Aurobindo, Divi's Labs up 4%

At 03:16 pm; the Nifty Pharma index, the sole gainer among sectoral indices, was up 2%, as compared to 0.49% decline in Nifty 50 index.

Sun Pharma extends rally on EIR from USFDA for Halol facility

The stock was up 4% to Rs 561 on BSE in early morning trade, extending its past five days 14% rally, after the company announced the resolution of regulatory compliance issues at Halol plant.

Sun Pharma says USFDA issues at Halol over, two specialty drugs may get nod

While the plant was served warning letter by US regulator in December 2015, product approvals were frozen in September 2014

Sun Pharma stock gains 8% as company clears FDA's Halol plant hurdle

The Halol plant was reinspected by the FDA in the March quarter, and had received three Form 483 observations

Sun Pharma rallies 6% post Q4 results

The stock rallied 6% to Rs 496 on the BSE in early morning trade after the drug maker reported a net profit of Rs 13.08 billion in March 2018 quarter.

Lower price erosion may finally bring sunny days for Sun Pharma

While the company, which derives 35 per cent of its consolidated sales from the US market, reported a 3 per cent fall over the year-ago quarter

Sun Pharma expects double digit sales growth in FY19

The company expects revenue growth on the back of three speciality drug launches in US and growth across markets

Sun Pharma Q4 consolidated net profit up 7% at Rs 13 billion

The company had reported a net profit of Rs 12.23 billion in the same period of the previous financial year.

Declining sale of key drug weighs on Sun Pharma, stock down 7% in 2 days

Sales of acne drug Absorica were down 26 per cent on a sequential basis in the March quarter